The Acquired (Autoimmune) Hemolytic Anemia drugs in development market research report provides comprehensive information on the therapeutics under development for Acquired (Autoimmune) Hemolytic Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Acquired (Autoimmune) Hemolytic Anemia. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Acquired (Autoimmune) Hemolytic Anemia and features dormant and discontinued products.

GlobalData tracks 99 drugs in development for Acquired (Autoimmune) Hemolytic Anemia by 89 companies/universities/institutes. The top development phase for Acquired (Autoimmune) Hemolytic Anemia is preclinical with 37 drugs in that stage. The Acquired (Autoimmune) Hemolytic Anemia pipeline has 92 drugs in development by companies and seven by universities/ institutes. Some of the companies in the Acquired (Autoimmune) Hemolytic Anemia pipeline products market are: Novartis, Vertex Pharmaceuticals and Annexon.

The key targets in the Acquired (Autoimmune) Hemolytic Anemia pipeline products market include Hemoglobin Subunit Beta (Beta Globin or Hemoglobin Beta Chain or HBB), Hemoglobin Subunit Gamma 1 (Gamma Globin or Gamma1 Globin or Hb F Agamma or Hemoglobin Gamma 1 Chain or Hemoglobin Gamma A Chain or HBG1), and B Cell Lymphoma/Leukemia 11A (B Cell CLL/Lymphoma 11A or COUP TF Interacting Protein 1 or Ecotropic Viral Integration Site 9 Protein Homolog or Zinc Finger Protein 856 or BCL11A).

The key mechanisms of action in the Acquired (Autoimmune) Hemolytic Anemia pipeline product include Hemoglobin Subunit Beta (Beta Globin or Hemoglobin Beta Chain or HBB) Activator with nine drugs in Phase II. The Acquired (Autoimmune) Hemolytic Anemia pipeline products include eight routes of administration with the top ROA being Intravenous and 13 key molecule types in the Acquired (Autoimmune) Hemolytic Anemia pipeline products market including Gene-Modified Cell Therapy, and Small Molecule.

Acquired (Autoimmune) Hemolytic Anemia overview

Acquired autoimmune hemolytic anemia (AIHA) is a rare blood disorder characterized by the immune system mistakenly attacking and destroying red blood cells. Red blood cells carry oxygen throughout the body, and their destruction leads to anemia (low red blood cell count), causing fatigue, pale skin, and other symptoms. AIHA can be classified into “warm” and “cold” types, depending on the temperature at which the antibodies bind to red blood cells. Warm AIHA is more common and occurs at body temperature, while cold AIHA happens at lower temperatures. Treatment may involve corticosteroids, immunosuppressive drugs, blood transfusions, and, in severe cases, splenectomy. Management aims to control the immune response and alleviate anemia-related symptoms.

For a complete picture of Acquired (Autoimmune) Hemolytic Anemia’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.